New Clinical Guideline
The Endocrine Society Unveils New Clinical Guideline Addressing the Endocrine Treatment of Persons with Gender Identityi Disorder
On the last september 17 th 2009, the The Endocrine Society had adopted a new guideline on transsexuals treatments. Here is the press release from last week:
Chevy Chase, MD—The Endocrine Society has released a new clinical practice guideline for endocrine treatment of transsexual persons. The guideline, “Endocrine Treatment of Transsexuali Persons: An Endocrine Society Clinical Practice Guideline,” appears in the September 2009 issue of the Journal of Clinical Endocrinologyi & Metabolism (JCEM), a publication of The Endocrine Society.
Transsexualism, or gender identity disorder (GID), is defined as a condition in which a patient experiences clinically significant distress due to strong and persistent cross-gender identification combined with a discomfort with their sex or a sense of inappropriateness in the gender role of that sex.
“Transsexual persons experiencing the confusion and stress associated with feeling ‘trapped’ in the wrong body, look to endocrinologists for treatment that can bring relief and resolution to their profound discomfort,” said Wylie Hembree, MD, of Columbia University in New York and chair of the task force that developed the guideline. “It is the purpose of this guideline to make science-based recommendations that will enable endocrinologists to provide safe and effective treatment for individuals diagnosed with GID.”
The clinical guideline recommends:
- The diagnosis of GID be made by a mental health professional;
- Against endocrine treatment of prepubertal children because a diagnosis of transsexualism in a child who has not yet gone through puberty cannot be made with certainty;
- Treating transsexual adolescents when they first exhibit signs of puberty by suppressing puberty until the age of 16 years, after which cross-sex hormones may be given;
- Treating transsexual adults by suppressing endogenous sex hormones, maintaining physiologic levels of gender-appropriate sex hormones and monitoring for known risks.
“The medical field will need further rigorous evaluation of the effectiveness and safety of all endocrine treatments of transsexual persons,” said Hembree. “Of specific concern are the effects of prolonged delay of puberty on bone growth and the long-term medical and psychological risks of sex re-assignment.”
Other members of the task force that developed this guideline include Peggy Cohen-Kettenis and Henriette Delemarre-van de Waal of VU Medical Center in The Netherlands; Louis Gooren; Walter Meyer of the University of Texas in Galveston, Tex.; Norman Spack of Harvard Medical School in Boston, Mass.; Vin Tangpricha of Emory University in Atlanta, Ga.; and Victor Montori of the Mayo Clinic in Rochester, Minn.
The full document is here.
You can also read the old work document about it from 2008